A worker checks syringes of the potential vaccine CoronaVac on the production line at Sinovac Biotech where the company is producing their potential COVID-19 vaccine CoronaVac on September 24, 2020 in Beijing, China. Sinovacs inactivated vaccine candidate, called CoronaVac, is among a number of companies in the global race to control the coronavirus pandemic. The company is running Phase 3 human trials in four countries and ramping up production to 300 million doses per year at a new manufacturing facility south of Beijing.
Image: Kevin Frayer/Getty Images
©2019 New York Times News Service